|
|
Article: Stressgen presents results of pediatric Phase II RRP trial at ICAAC supporting pivotal Phase III trial; Projected That More Than 50 Surgeries Avoided During Year After Treatment with HspE7.
- Article from:
- PR Newswire
- Article date:
- September 16, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Stressgen Biotechnologies Corporation (TSX:SSB) today presented interim data from its Phase II trial with HspE7 in recurrent respiratory papillomatosis (RRP), a seriously debilitating and sometimes life-threatening condition for children, at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, Illinois. These data will be available on the Company's website at http://www.stressgen.com/.
The primary endpoint of the Phase II trial evaluated the interval between surgeries following treatment with HspE7 compared to the pretreatment surgical interval. The increase in the first post-treatment intersurgical interval is statistically ...